0001445866-19-001108.txt : 20190906 0001445866-19-001108.hdr.sgml : 20190906 20190906162143 ACCESSION NUMBER: 0001445866-19-001108 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190901 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20190906 DATE AS OF CHANGE: 20190906 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GB SCIENCES INC CENTRAL INDEX KEY: 0001165320 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 593733133 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55462 FILM NUMBER: 191079900 BUSINESS ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 BUSINESS PHONE: (844) 843-2569 MAIL ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 FORMER COMPANY: FORMER CONFORMED NAME: Growblox Sciences, Inc. DATE OF NAME CHANGE: 20140603 FORMER COMPANY: FORMER CONFORMED NAME: Signature Exploration & Production Corp. DATE OF NAME CHANGE: 20080602 FORMER COMPANY: FORMER CONFORMED NAME: Diabetic Treatment Centers of America, Inc. DATE OF NAME CHANGE: 20040812 8-K 1 gblx_8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 Or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 1, 2019

 

GB Sciences, Inc.

(Exact name of Registrant as specified in its charter)

 

 

Nevada

(State or other Jurisdiction of
Incorporation or organization)

000-55462

(Commission File Number)

59-3733133

(IRS Employer I.D. No.)

 

3550 W. Teco Avenue

Las Vegas, Nevada 89118

Phone: (844) 843-2569

(Address, including zip code, and telephone number, including area code, of

registrant’s principal executive offices)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

☐ Soliciting material pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l 4a- l 2) 

 

☐ Pre-commencement communications pursuant to Rule l 4d-2(b) under the Exchange Act (17 CFR 240. l 4d-2(b)) 

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. l 3e-4(c)) 

 

 

Item 5.02 Departure and Appointment of Certain Officers.

 

On September 1, 2019, the Registrant, GB Sciences, Inc. (“GB Sciences” or “Company”), and Ksenia Griswold terminated their relationship wherein Ms. Griswold had been serving as an executive officer of the GB Sciences in the capacity of Chief Financial Officer and Chief Operating Officer.  GB Sciences is appreciative of the contribution Ms. Griswold made to the Company and wishes her every success in the future.  

 

On September 5, 2019, the Board of Directors appointed Zach Swarts Interim Chief Financial Officer.  Mr. Swarts has served as the Company’s director of finance and accounting since October 2017. Prior to his employment with the Company, he worked for Swarts & Swarts, CPAs as the manager of the forensic accounting and litigation support department from April 2016 to October 2017. From January 2014 to April 2016, he worked in the Las Vegas, Nevada office of Ernst & Young, LLP, where he was an audit senior at the time of his departure.

1

 

SIGNATURE PAGE

 

Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

                     GB Sciences, Inc.

 

 

 

 

 

 

Dated: September 6, 2019

 

By:

/s/ John Poss

 

 

 

 

John Poss

 

 

 

 

Chief Executive Officer

 

2